Menlo Therapeutics Inc
NASDAQ:MNLO (9/4/2020, 7:18:36 PM)
After market: 1.38 +0.03 (+2.22%)1.35
-0.03 (-2.17%)
Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California.
Menlo Therapeutics Inc
520 U.S. HIGHWAY 22 SUITE 204
BRIDGEWATER NJ 08807
P: 800-775-7936
CEO: Steven Basta
Menlo Therapeutics (MNLO) changed its name to Vyne Therapeutics and will trade under the symbol to 'VYNE'; effective trading today."We are excited to launch our new corporate identity as VYNE Therapeutics today, and are honored to be marking this important milestone in our company's history by ringing the Nasdaq closing bell," president & CEO David Domzalski commented.No change in outstanding common shares and stockholders rights.
Will commence trading under new Nasdaq Ticker "VYNE", September 8, 2020
Here you can normally see the latest stock twits on MNLO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: